FDA
-
-
-
-
-
-
-
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Vaxart (VXRT) Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults
-
-
-
-
-
-
-
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
-
-
-
-
-
-
-
Vaxart Provides Business Update
-
-
-
-
-
-
-
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
-
-
-
-
-
-
-
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

